InspireMD (NYSE:NSPR) this week posted third-quarter results that beat the overall consensus on Wall Street.
The Tel Aviv, Israel-based company reported net losses of $4.5 million, or -58¢ per share, on sales of $1.43 million for the three months ended Sept. 30, for a sales growth of 33.61% compared with Q3 2021.
Earnings per share were 15¢ ahead of The Street, where analysts were looking for sales of $1.4 million.
“During the third quarter, we continued to gain share in our key European markets, contributing to nearly 40% CGuard revenue growth over the prior year period. We continue to work with our Notified Body to secure our CE Mark certification under the MDR, which currently expires November 12, while preparing our customers and distributors with sufficient inventory to mitigate as best as possible any potential delay in the recertification process,” CEO Marvin Slosman said in a news release.
“At the same time, our U.S. IDE trial now has 24 sites enrolling patients. We continue to anticipate having the trial fully enrolled by approximately end of Q1 of next year, a critical step forward in our goal to gain eventual marketing approval in the U.S.”
InspireMD did not provide a financial outlook for the remainder of the year.
Shares of INSP were at a standstill in premarket trading.
